Anzeige
Mehr »
Sonntag, 12.04.2026 - Börsentäglich über 12.000 News
0,01% von 1 BILLIONEN USD = 100 MILLIONEN USD - Und UberDoc ist gerade erst an die Börse gegangen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4LY | ISIN: US00773J2024 | Ticker-Symbol: 3920
Tradegate
10.04.26 | 19:13
44,200 Euro
+0,91 % +0,400
1-Jahres-Chart
SPYRE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPYRE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
43,40043,60011.04.
43,20044,40010.04.

Aktueller Chart SPYRE THERAPEUTICS Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
SPYRE THERAPEUTICS INC-Investoren interessieren sich auch für diese Wertpapiere
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated...
► Artikel lesen
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three...
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesMr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S....
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateNew Drug Application (NDA) for QTORIN rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S....
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual MeetingPoster #76954 highlights QTORIN rapamycin's single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization...
► Artikel lesen
Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big SwingsWASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen